

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53841

**Title:** Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

**Reviewer's code:** 03767436

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2019-12-31

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-02-17 07:44

**Reviewer performed review:** 2020-02-17 08:03

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Generally speaking, the manuscript is well designed and discussed. The conclusions seem appropriate and rationale, emphasizing the need for further prospective studies to improve outcomes in HER2+ ILC. However, some minor changes should be performed:

1. Please check the few spelling grammatical error and typos in the text.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53841

**Title:** Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

**Reviewer's code:** 00068720

**Position:** Peer Reviewer

**Academic degree:** MSc

**Professional title:** Attending Doctor, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2019-12-31

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-02-14 14:23

**Reviewer performed review:** 2020-02-17 15:49

**Review time:** 3 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

In this paper the authors reported HER2+ ILC was more likely to have poorer prognostic features such as ER-, PR- and higher tumour grade, and have a poorer survival.. The paper is of some scientific interest and clinical value. There are some questions: 1. The authors should addressed more detailed clinical pathological parameters especially follow-up for all patients in “Materials and Methods”. 2. The authors should reanalyze multivariate analysis after including the all clinicopathological parameter such as lymph-vascular invasion, lymph node metastasis etc. 3. There are many small errors in this manuscript, for example, the title of journal in references is inconsistent.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53841

**Title:** Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

**Reviewer's code:** 00070509

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2019-12-31

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-02-17 00:34

**Reviewer performed review:** 2020-02-20 00:17

**Review time:** 2 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

Title: HER2 positive rates in Invasive Lobular Breast Carcinoma: The Singapore Experience This manuscript describes the prevalence and prognostic factors of HER2 positive ILC in the Singapore cases. The authors mentioned the limits of this study. Nevertheless, this manuscript is very informative and well written.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53841

**Title:** Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

**Reviewer's code:** 03252981

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Academic Research, Associate Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2019-12-31

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-02-15 02:51

**Reviewer performed review:** 2020-02-24 00:39

**Review time:** 8 Days and 21 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

The manuscript described the prevalence, survival and prognostic factors in HER2-positive invasive lobular carcinoma in Singapore. The analyses of patient data looks appropriate and the results are reasonable. However, there are a couple of criticisms. The patients analyzed in the study were diagnosed as breast cancer and treated from 1985 to 2018. It needs to be confirmed that all histologies and immunostainings were reviewed. That is because ASCO-CAP guideline was changed a couple of times. The data needs to be carefully reviewed. In addition, anti-HER2 therapy began around 2000. The authors described 54% patient received HER2-directed therapy. As the authors stated, this is reasonable since the number of patients from 1985 to 2000 and that from 2000 to 2018 may be approximately equal. However, the data on prognosis may be biased. The prognostic factor needs to be carefully reviewed. It is also plausible that the analysis separated into before 2000 and after 2000. There are many strange sentences and wordings. The manuscript needs thorough revision.